# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintai...
Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering fro...
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect ...
Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase...
Stephens & Co. analyst Sudan Loganathan initiates coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight rati...
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate ...
- SEC Filing
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...